On the stock market since 2023, it operates in the world of health and science. It has 16 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
There is $113.1M in the vault; even if every debt were paid off, $113.0M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 23 buys and 11 sells. Management buying with its own money is usually read as a good sign.
A loss of $51.0M against $0 in annual sales.
This stock swings about 3.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, SGMT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SGMT is a high-risk stock — not yet profitable, and its future rides on its product catching on.